Humacyte’s (HUMA) Buy Rating Reaffirmed at Benchmark

Benchmark reaffirmed their buy rating on shares of Humacyte (NASDAQ:HUMA) in a research report sent to investors on Tuesday, Benzinga reports. Benchmark currently has a $15.00 price target on the stock.

Several other equities analysts have also recently weighed in on the company. Piper Sandler restated a neutral rating and set a $4.00 price objective on shares of Humacyte in a research note on Tuesday, March 26th. Cantor Fitzgerald reiterated an overweight rating and issued a $7.00 target price on shares of Humacyte in a report on Monday, April 1st.

Humacyte Stock Performance

Shares of HUMA stock opened at $5.67 on Tuesday. The company has a current ratio of 8.37, a quick ratio of 8.37 and a debt-to-equity ratio of 0.61. The firm has a fifty day simple moving average of $6.02 and a two-hundred day simple moving average of $4.24. Humacyte has a 12 month low of $1.96 and a 12 month high of $9.97. The firm has a market capitalization of $675.18 million, a PE ratio of -5.67 and a beta of 1.51.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings results on Friday, May 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). Analysts forecast that Humacyte will post -0.95 EPS for the current fiscal year.

Insider Activity

In related news, Director Gordon M. Binder purchased 50,000 shares of Humacyte stock in a transaction that occurred on Wednesday, May 15th. The stock was bought at an average price of $6.78 per share, for a total transaction of $339,000.00. Following the completion of the transaction, the director now owns 160,000 shares in the company, valued at $1,084,800. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, Director Gordon M. Binder purchased 50,000 shares of the firm’s stock in a transaction dated Wednesday, May 15th. The stock was bought at an average price of $6.78 per share, for a total transaction of $339,000.00. Following the purchase, the director now directly owns 160,000 shares in the company, valued at approximately $1,084,800. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Brady W. Dougan sold 271,518 shares of the company’s stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $7.30, for a total value of $1,982,081.40. Following the completion of the transaction, the director now owns 4,559,140 shares in the company, valued at approximately $33,281,722. The disclosure for this sale can be found here. In the last ninety days, insiders acquired 54,412 shares of company stock valued at $369,107 and sold 1,628,820 shares valued at $12,464,121. Insiders own 23.10% of the company’s stock.

Institutional Investors Weigh In On Humacyte

Large investors have recently added to or reduced their stakes in the company. Victory Capital Management Inc. bought a new position in Humacyte during the fourth quarter worth about $29,000. China Universal Asset Management Co. Ltd. grew its stake in Humacyte by 350.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,986 shares of the company’s stock valued at $34,000 after buying an additional 9,325 shares in the last quarter. SG Americas Securities LLC raised its holdings in Humacyte by 52.8% during the 4th quarter. SG Americas Securities LLC now owns 16,340 shares of the company’s stock valued at $46,000 after acquiring an additional 5,645 shares during the period. Powell Investment Advisors LLC lifted its position in shares of Humacyte by 75.0% during the fourth quarter. Powell Investment Advisors LLC now owns 21,000 shares of the company’s stock worth $60,000 after acquiring an additional 9,000 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. bought a new position in shares of Humacyte in the fourth quarter worth $28,000. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.